AstraZeneca Sells Zoladex to TerSera in $250M Deal

Source: AstraZeneca

Feb 21, 2017

AstraZeneca has struck a deal with TerSera Therapeutics LLC for the commercial rights to Zoladex (goserelin acetate implant) in the United States and Canada for $150 million. Used to treat prostate cancer, breast cancer and certain benign gynaecological disorders, the drug was first approved in 1989.

AstraZeneca will also receive sales-related income up to $70 million. AstraZeneca will manufacture and supply Zoladex to TerSera.

In 2016, sales for Zoladex were $69 million in the United States and Canada and $816 million globally. The transaction is expected to complete in the first quarter of 2017. AstraZeneca will maintain a significant ongoing interest in Zoladex in the United States and Canada.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments